GNLX GENELUX Corp
Nasdaq · SEC CIK 1231457 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $330.8K 19 sales by 6 insiders
- Filings on record
- 167 since 2023-01-30, latest 2026-09-02 19:05
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Zindrick Thomas | Pres, CEO | — | $117.7K |
| Thomas John | Dir | — | $108.8K |
| Smither John W | Dir | — | $34.9K |
| Cappello Joseph | Chief Technical Off | — | $34.0K |
| Yu Yong | SVP, Clinical Development | — | $32.6K |
| Smalling Ralph | Head of Regulatory | — | $2,804 |
| Pulisic Matthew | CFO | — | — |
| Mirabelli Mary | Dir | — | — |
| Groen Eric | GC | — | — |
| Tyree James L | Dir | — | — |
Transactions 160
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-02 19:05 | 2026-08-31 | GNLX | Cappello Joseph | Chief Technical Off | S - Sale | $2.74 | -10.3K | 318.5K | -3% | -$28.1K | |
| 2026-09-02 19:05 | 2026-08-31 | GNLX | Zindrick Thomas | Pres, CEO | S - Sale | $2.67 | -34.5K | 1.23M | -3% | -$91.9K | |
| 2026-09-02 19:05 | 2026-08-31 | GNLX | Yu Yong | CSO | S - Sale | $2.75 | -9,683 | 258.7K | -4% | -$26.7K | |
| 2026-08-04 20:20 | 2026-08-04 | GNLX | Yu Yong | CSO | S - Sale | $2.94 | -653 | 268.4K | -0.2% | -$1,922 | |
| 2026-08-04 20:20 | 2026-08-04 | GNLX | Cappello Joseph | Chief Technical Off | S - Sale | $2.95 | -653 | 328.7K | -0.2% | -$1,924 | |
| 2026-08-04 20:20 | 2026-08-04 | GNLX | Zindrick Thomas | Pres, CEO | S - Sale | $2.95 | -3,023 | 1.26M | -0.2% | -$8,905 | |
| 2026-07-02 16:35 | 2026-07-01 | GNLX | Smither John W | Dir | S - Sale | $2.91 | -12.0K | 91.4K | -12% | -$34.9K | |
| 2026-06-18 19:05 | 2026-06-16 | GNLX | Pulisic Matthew | CFO | A - Grant | $0.00 | +278.9K | 278.9K | New | $0 | |
| 2026-06-18 19:05 | 2026-06-16 | GNLX | Groen Eric | GC | A - Grant | $0.00 | +234.0K | 234.0K | New | $0 | |
| 2026-06-18 19:05 | 2026-06-16 | GNLX | Cappello Joseph | Chief Technical Off | A - Grant | $0.00 | +174.8K | 329.4K | +113% | $0 | |
| D | 2026-06-18 19:05 | 2026-06-16 | GNLX | Tyree James L | Dir | A - Grant | $0.00 | +28.4K | 96.5K | +42% | $0 |
| 2026-06-18 19:05 | 2026-06-16 | GNLX | Zindrick Thomas | Pres, CEO | A - Grant | $0.00 | +730.6K | 1.26M | +137% | $0 | |
| D | 2026-06-18 19:05 | 2026-06-16 | GNLX | Thomas John | Dir | A - Grant | $0.00 | +28.4K | 501.2K | +6% | $0 |
| D | 2026-06-18 19:05 | 2026-06-16 | GNLX | Mirabelli Mary | Dir | A - Grant | $0.00 | +28.4K | 102.7K | +38% | $0 |
| 2026-06-18 19:05 | 2026-06-16 | GNLX | Yu Yong | CSO | A - Grant | $0.00 | +119.3K | 269.0K | +80% | $0 | |
| D | 2026-06-18 19:05 | 2026-06-16 | GNLX | Smither John W | Dir | A - Grant | $0.00 | +28.4K | 103.4K | +38% | $0 |
| 2026-06-04 20:35 | 2026-06-03 | GNLX | Smalling Ralph | Head of Regulatory | S - Sale | $2.93 | -192 | 67.6K | -0.3% | -$562.56 | |
| T | 2026-06-02 20:35 | 2026-06-01 | GNLX | Thomas John | Dir | S - Sale | $2.98 | -10.0K | 472.8K | -2% | -$29.8K |
| 2026-05-12 20:30 | 2026-05-11 | GNLX | Yu Yong | CSO | S - Sale | $2.97 | -605 | 149.7K | -0.4% | -$1,798 | |
| 2026-05-12 20:30 | 2026-05-11 | GNLX | Cappello Joseph | Chief Technical Off | S - Sale | $2.97 | -605 | 154.5K | -0.4% | -$1,799 | |
| 2026-05-12 20:30 | 2026-05-11 | GNLX | Zindrick Thomas | Pres, CEO | S - Sale | $2.94 | -2,798 | 532.1K | -0.5% | -$8,226 | |
| 2026-05-12 20:30 | 2026-05-11 | GNLX | Smalling Ralph | Head of Regulatory | S - Sale | $2.98 | -270 | 67.8K | -0.4% | -$804.49 | |
| M | 2026-03-26 | 2026-03-24+ | GNLX | Smalling Ralph | Head of Regulatory | S - Sale | $2.46 | -585 | 68.1K | -0.9% | -$1,437 |
| 2026-03-26 | 2026-03-24 | GNLX | Yu Yong | SVP, Clinical Development | S - Sale | $2.42 | -906 | 144.9K | -0.6% | -$2,193 | |
| 2026-03-26 | 2026-03-24 | GNLX | Cappello Joseph | Chief Technical Off | S - Sale | $2.42 | -906 | 155.2K | -0.6% | -$2,193 | |
| 2026-03-26 | 2026-03-24 | GNLX | Zindrick Thomas | Pres, CEO | S - Sale | $2.42 | -3,582 | 534.8K | -0.7% | -$8,668 | |
| 2026-03-03 | 2026-03-02 | GNLX | Thomas John | Dir | S - Sale | $2.90 | -10.0K | 482.8K | -2% | -$29.0K | |
| M | 2025-12-11 | 2025-08-21+ | GNLX | Yu Yong | SVP, Clinical Development | S - Sale | $3.83 | -4,192 | 145.8K | -3% | -$16.0K |
| M | 2025-12-11 | 2025-08-21+ | GNLX | Cappello Joseph | Chief Technical Off | S - Sale | $3.88 | -3,706 | 157.0K | -2% | -$14.4K |
| M | 2025-12-11 | 2025-08-21+ | GNLX | Zindrick Thomas | Pres, CEO | S - Sale | $3.87 | -17.2K | 542.9K | -3% | -$66.4K |
| M | 2025-12-09 | 2025-08-21+ | GNLX | Smalling Ralph | Head of Regulatory | S - Sale | $3.75 | -2,332 | 68.7K | -3% | -$8,744 |
| 2025-12-02 | 2025-12-01 | GNLX | Thomas John | Dir | S - Sale | $5.00 | -10.0K | 492.8K | -2% | -$50.0K | |
| D | 2025-09-03 | 2025-09-01 | GNLX | Smalling Ralph | Head of Regulatory | A - Grant | $0.00 | +10.0K | 71.0K | +16% | $0 |
| D | 2025-08-29 | 2025-08-27 | GNLX | Cappello Joseph | Chief Technical Off | A - Grant | $0.00 | +107.5K | 159.8K | +206% | $0 |
| D | 2025-08-29 | 2025-08-27 | GNLX | Thomas John | Dir | A - Grant | $0.00 | +22.3K | 502.8K | +5% | $0 |
| D | 2025-08-29 | 2025-08-27 | GNLX | Yu Yong | SVP, Clinical Development | A - Grant | $0.00 | +101.5K | 150.0K | +209% | $0 |
| D | 2025-08-29 | 2025-08-27 | GNLX | Zindrick Thomas | Pres, CEO | A - Grant | $0.00 | +361.2K | 554.2K | +187% | $0 |
| D | 2025-08-29 | 2025-08-27 | GNLX | Tyree James L | Dir | A - Grant | $0.00 | +22.3K | 68.1K | +49% | $0 |
| D | 2025-08-29 | 2025-08-27 | GNLX | Smither John W | Dir | A - Grant | $0.00 | +22.3K | 75.0K | +42% | $0 |
| D | 2025-08-29 | 2025-08-27 | GNLX | Mirabelli Mary | Dir | A - Grant | $0.00 | +22.3K | 73.3K | +44% | $0 |
| D | 2025-08-29 | 2025-08-27 | GNLX | Smalling Ralph | Head of Regulatory | A - Grant | $0.00 | +26.2K | 61.0K | +75% | $0 |
| 2025-06-24 | 2025-06-06 | GNLX | Thomas John | Dir | G - Gift | $0.00 | -25.0K | 480.5K | -5% | $0 | |
| 2025-05-13 | 2025-05-12 | GNLX | Cappello Joseph | VP, Pharmaceutical Development | S - Sale | $2.92 | -4,737 | 52.3K | -8% | -$13.8K | |
| 2025-05-13 | 2025-05-12 | GNLX | Ryder Sean | GC | S - Sale | $2.92 | -4,475 | 47.6K | -9% | -$13.1K | |
| 2025-05-13 | 2025-05-12 | GNLX | Smalling Ralph | Head of Regulatory | S - Sale | $2.92 | -1,259 | 34.8K | -3% | -$3,676 | |
| 2025-05-13 | 2025-05-12 | GNLX | Zindrick Thomas | Pres, CEO, Dir | S - Sale | $2.92 | -10.8K | 191.4K | -5% | -$31.4K | |
| 2025-05-13 | 2025-05-12 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale | $2.92 | -5,579 | 47.6K | -10% | -$16.3K | |
| 2025-04-17 | 2025-03-14 | GNLX | Smalling Ralph | Head of Regulatory | A - Grant | $0.00 | +4,172 | 36.0K | +13% | $0 | |
| 2025-04-17 | 2025-03-14 | GNLX | Ryder Sean | GC | A - Grant | $0.00 | +10.7K | 52.1K | +26% | $0 | |
| 2025-04-17 | 2025-03-14 | GNLX | Zindrick Thomas | Pres, CEO, Dir | A - Grant | $0.00 | +30.3K | 202.2K | +18% | $0 | |
| 2025-04-17 | 2025-03-14 | GNLX | Yu Yong | VP, Clinical Trial Ops | A - Grant | $0.00 | +13.3K | 53.2K | +33% | $0 | |
| 2025-04-17 | 2025-03-14 | GNLX | Cappello Joseph | VP, Pharmaceutical Development | A - Grant | $0.00 | +13.3K | 57.0K | +31% | $0 | |
| 2024-12-30 | 2024-12-30 | GNLX | Tyree James L | Dir | S - Sale | $2.46 | -3,460 | 45.8K | -7% | -$8,512 | |
| D | 2024-12-20 | 2024-12-18 | GNLX | Smalling Ralph | Head of Regulatory | A - Grant | $0.00 | +15.5K | 31.8K | +95% | $0 |
| D | 2024-12-20 | 2024-12-18 | GNLX | Cappello Joseph | VP, Pharmaceutical Development | A - Grant | $0.00 | +29.0K | 43.7K | +198% | $0 |
| D | 2024-12-20 | 2024-12-18 | GNLX | Zindrick Thomas | Pres, CEO, Dir | A - Grant | $0.00 | +134.5K | 171.9K | +360% | $0 |
| D | 2024-12-20 | 2024-12-18 | GNLX | Yu Yong | VP, Clinical Trial Ops | A - Grant | $0.00 | +29.0K | 39.9K | +267% | $0 |
| D | 2024-12-20 | 2024-12-18 | GNLX | Zak Lourie S. | CFO | A - Grant | $0.00 | +41.6K | 82.5K | +102% | $0 |
| D | 2024-12-20 | 2024-12-18 | GNLX | Ryder Sean | GC | A - Grant | $0.00 | +22.0K | 41.4K | +113% | $0 |
| 2024-12-18 | 2024-12-16 | GNLX | Cappello Joseph | VP, Pharmaceutical Development | S - Sale | $2.34 | -6,300 | 14.7K | -30% | -$14.7K | |
| 2024-12-18 | 2024-12-16 | GNLX | Zindrick Thomas | Pres, CEO, Dir | S - Sale | $2.34 | -14.3K | 37.4K | -28% | -$33.5K | |
| 2024-12-18 | 2024-12-16 | GNLX | Smalling Ralph | Head of Regulatory | S - Sale | $2.34 | -2,510 | 16.3K | -13% | -$5,873 | |
| 2024-12-18 | 2024-12-16 | GNLX | Zak Lourie S. | CFO | S - Sale | $2.34 | -2,103 | 40.8K | -5% | -$4,921 | |
| MI | 2024-09-13 | 2024-09-12+ | GNLX | Szalay Aladar | 10% | S - Sale | $2.65 | -64.9K | 632.9K | -9% | -$171.8K |
| 2024-09-12 | 2024-09-11 | GNLX | Tyree James L | Dir | S - Sale | $2.60 | -1,730 | 47.5K | -4% | -$4,498 | |
| MI | 2024-09-11 | 2024-09-09+ | GNLX | Szalay Aladar | 10% | S - Sale | $2.62 | -75.1K | 664.7K | -10% | -$196.5K |
| I | 2024-09-06 | 2024-09-03 | GNLX | Szalay Aladar | 10% | S - Sale | $2.09 | -42.8K | 739.8K | -5% | -$89.5K |
| MI | 2024-08-30 | 2024-08-28+ | GNLX | Szalay Aladar | 10% | S - Sale | $2.09 | -265.6K | 782.6K | -25% | -$554.0K |
| MI | 2024-08-27 | 2024-08-23+ | GNLX | Szalay Aladar | 10% | S - Sale | $2.19 | -91.6K | 1.05M | -8% | -$200.5K |
| D | 2024-08-05 | 2024-08-01 | GNLX | Thomas John | Dir | A - Grant | $0.00 | +39.5K | 505.5K | +8% | $0 |
| D | 2024-08-05 | 2024-08-01 | GNLX | Mirabelli Mary | Dir | A - Grant | $0.00 | +39.5K | 52.0K | +317% | $0 |
| D | 2024-08-05 | 2024-08-01 | GNLX | Smither John W | Dir | A - Grant | $0.00 | +39.5K | 52.7K | +300% | $0 |
| D | 2024-08-05 | 2024-08-01 | GNLX | Tyree James L | Dir | A - Grant | $0.00 | +39.5K | 49.3K | +407% | $0 |
| M | 2024-07-08 | 2024-02-19+ | GNLX | Smalling Ralph | Head of Regulatory | A - Grant | $0.00 | +2,723 | 13.9K | +24% | $0 |
| 2024-07-08 | 2024-06-24 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale | $2.12 | -6,849 | 10.9K | -39% | -$14.5K | |
| M | 2024-07-08 | 2024-02-19+ | GNLX | Yu Yong | VP, Clinical Trial Ops | A - Grant | $0.00 | +15.2K | 17.7K | +609% | $0 |
| M | 2024-07-08 | 2024-02-19+ | GNLX | Zak Lourie S. | CFO | A - Grant | $0.00 | +5,072 | 32.5K | +19% | $0 |
| M | 2024-07-08 | 2024-02-19+ | GNLX | Jewett Caroline | Head of Quality | A - Grant | $0.00 | +4,755 | 25.9K | +22% | $0 |
| 2024-07-08 | 2024-06-24 | GNLX | Jewett Caroline | Head of Quality | S - Sale | $2.12 | -4,961 | 16.2K | -23% | -$10.5K | |
| M | 2024-07-08 | 2024-02-19+ | GNLX | Cappello Joseph | VP, Pharmaceutical Development | A - Grant | $0.00 | +15.2K | 9,396 | New | $0 |
| M | 2024-07-08 | 2024-02-19+ | GNLX | Ryder Sean | GC | A - Grant | $0.00 | +12.2K | 13.5K | +937% | $0 |
| 2024-07-08 | 2024-06-24 | GNLX | Ryder Sean | GC | S - Sale | $2.12 | -5,496 | 19.4K | -22% | -$11.7K | |
| M | 2024-07-08 | 2024-02-19+ | GNLX | Zindrick Thomas | Pres, CEO, Dir | A - Grant | $0.00 | +34.6K | 23.0K | New | $0 |
| D | 2024-06-07 | 2024-05-29 | GNLX | Yu Yong | VP, Clinical Trial Ops | P - Purchase | — | +2,500 | 2,500 | New | — |
| D | 2024-06-07 | 2024-05-29 | GNLX | Smalling Ralph | Head of Regulatory | P - Purchase | — | +1,250 | 13.3K | +10% | — |
| D | 2024-06-07 | 2024-05-29 | GNLX | Tyree James L | Dir | P - Purchase | — | +6,250 | 9,710 | +181% | — |
| D | 2024-06-07 | 2024-05-29 | GNLX | Thomas John | Dir | P - Purchase | — | +2,500 | 466.0K | +0.5% | — |
| DI | 2024-06-07 | 2024-05-29 | GNLX | Zindrick Thomas | Pres, CEO, Dir | P - Purchase | — | +200.0K | 200.0K | New | — |
| D | 2024-06-07 | 2024-05-29 | GNLX | Smither John W | Dir | P - Purchase | — | +6,250 | 13.2K | +90% | — |
| D | 2024-06-07 | 2024-05-29 | GNLX | Mirabelli Mary | Dir | P - Purchase | — | +8,000 | 12.5K | +179% | — |
| D | 2024-06-07 | 2024-05-29 | GNLX | Zak Lourie S. | CFO | P - Purchase | — | +31.2K | 31.2K | New | — |
| D | 2024-06-07 | 2024-05-29 | GNLX | Ryder Sean | GC | P - Purchase | — | +10.0K | 10.6K | +1,748% | — |
| MI | 2024-05-15 | 2024-05-13+ | GNLX | Szalay Aladar | 10% | S - Sale | $3.62 | -36.0K | 1.16M | -3% | -$130.3K |
| MI | 2024-05-09 | 2024-05-07+ | GNLX | Szalay Aladar | 10% | S - Sale | $3.77 | -19.9K | 1.19M | -2% | -$75.3K |
| MI | 2024-05-01 | 2024-04-29+ | GNLX | Szalay Aladar | 10% | S - Sale | $3.23 | -60.0K | 1.20M | -5% | -$194.0K |
| MI | 2024-04-24 | 2024-04-22+ | GNLX | Szalay Aladar | 10% | S - Sale | $3.50 | -44.4K | 1.26M | -3% | -$155.6K |
| MI | 2024-04-18 | 2024-04-16+ | GNLX | Szalay Aladar | 10% | S - Sale | $3.59 | -71.4K | 1.30M | -5% | -$256.2K |
| M | 2023-12-18 | 2023-12-15 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale | $13.16 | -32.5K | 5,803 | -85% | -$428.2K |
| M | 2023-12-14 | 2023-12-13 | GNLX | Thomas John | Dir | S - Sale | $13.38 | -9,000 | 465.4K | -2% | -$120.4K |
| M | 2023-12-14 | 2023-12-13 | GNLX | Tyree James L | Dir | S - Sale | $13.21 | -9,000 | 6,807 | -57% | -$118.9K |
Purchase Sale Sale after option exercise All abbreviations